Kimmtrak (Tebentafusp)

Tebentafusp, the active ingredient in Kimmtrak, is a ImmTAC (immune‑mobilizing monoclonal T‑cell receptor) bispecific fusion protein presented as an intravenous infusion for intravenous use. It is indicated for the treatment of metastatic uveal melanoma in adult patients whose tumors express gp100 and who are HLA‑A*02:01 positive.

GNH USA supplies Kimmtrak as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Kimmtrak is used in the immune‑oncology pathway to target metastatic uveal melanoma.

Metastatic uveal melanoma: improves overall survival by redirecting patient T‑cells to gp100‑expressing tumor cells.

Common Side Effects: - Infusion‑related reactions such as chills, fever, and hypotension. - Cytokine release syndrome presenting as flu‑like symptoms. - Rash or pruritus at the infusion site. - Fatigue and mild nausea. - Transient liver enzyme elevations. - Headache or dizziness.

Serious or Rare Side Effects: - Severe cytokine release syndrome requiring intensive care. - Cardiac arrhythmias or myocarditis. - Neurotoxicity including confusion or seizures. - Pulmonary edema or acute respiratory distress. - Anaphylaxis or severe hypersensitivity reactions. - Significant hepatic failure or bilirubin rise.

Before initiating therapy, clinicians should assess baseline organ function and monitor for immune‑mediated events.

Monitor cytokine release syndrome: observe vital signs during and after infusion. Cardiac monitoring: obtain ECG and watch for arrhythmias. Liver function tests: check ALT/AST before each dose. Infection risk: avoid use in patients with uncontrolled active infections. Concomitant immunotherapies: evaluate risk of additive immune activation. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tebentafusp may interact with other agents that modulate immune responses or cytokine activity.

Major Interactions (Avoid): - Concurrent use of other T‑cell engaging immunotherapies that could amplify cytokine release. - Live vaccines administered during treatment due to risk of uncontrolled infection. - High‑dose corticosteroids that may blunt therapeutic immune activation.

Moderate Interactions (Monitor Closely): - Anticoagulants: increased bleeding risk if infusion‑related thrombocytopenia occurs. - QT‑prolonging drugs: monitor cardiac rhythm during cytokine surge. - Hepatotoxic agents: watch liver enzymes for additive injury. - Immunosuppressants: adjust dosing and monitor for reduced efficacy.